文献速递药物相互作用

瑞莎珠单抗治疗12周对中度至重度斑块状银屑病患者CYP450探针底物药代动力学无影响

Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
PubMed 文献 · Clin Pharmacokinet · 2019-01-01

本研究在中重度慢性斑块状银屑病患者(n=21)中采用鸡尾酒法评估瑞莎珠单抗对CYP1A2、CYP2C9、CYP2C19、CYP2D6和CYP3A体内活性的影响。患者在第1天和第98天分别服用敏感探针底物,其间接受12周瑞莎珠单抗150mg每4周皮下注射。结果显示各探针底物AUC∞比值的90%CI均在0.8-1.25等效范围内,瑞莎珠单抗不影响上述CYP酶活性,无经这些酶介导的药物相互作用潜力。

要点

  • 瑞莎珠单抗12周治疗不影响CYP1A2、CYP2C9、CYP2C19、CYP2D6和CYP3A的体内活性
  • 各CYP探针底物AUC∞比值的90%CI均在0.8-1.25等效范围内
  • 瑞莎珠单抗无经上述CYP酶介导的药物相互作用潜力

核心结论

  • 瑞莎珠单抗不影响中重度斑块状银屑病患者CYP1A2、CYP2C9、CYP2C19、CYP2D6和CYP3A的体内活性,无经这些酶介导的药物相互作用潜力。

研究设计与样本

  • 单臂自身对照研究,纳入21例中重度慢性斑块状银屑病患者,采用CYP探针底物鸡尾酒法。
  • 第1天口服探针底物:咖啡因100mg(CYP1A2)、华法林10mg(CYP2C9)、奥美拉唑20mg(CYP2C19)、美托洛尔50mg(CYP2D6)、咪达唑仑2mg(CYP3A)。
  • 第8天至第92天皮下注射瑞莎珠单抗150mg每4周一次,共12周,第98天再次服用相同鸡尾酒探针底物。

主要发现

  • 各CYP探针底物合用瑞莎珠单抗与不用瑞莎珠单抗的AUC∞比值90%CI均在0.8-1.25等效范围内。
  • Cmax结果类似,仅奥美拉唑Cmax的90%CI下限(0.73)略低于默认等效限。
  • 合用瑞莎珠单抗与不用瑞莎珠单抗的代谢物/原型药Cmax或AUC比值无差异。
  • 瑞莎珠单抗谷浓度显著超过银屑病III期方案(150mg皮下注射,第0、4周及此后每12周)的谷浓度。

关键数值与推荐

  • AUC∞比值90%CI等效范围:0.8-1.25。
  • 奥美拉唑Cmax的90%CI下限为0.73,略低于默认等效限0.8。

临床怎么用

  • 银屑病患者接受瑞莎珠单抗治疗时,无需因CYP1A2、CYP2C9、CYP2C19、CYP2D6或CYP3A介导的相互作用而调整合用药物剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to characterize the effects of risankizumab on the in vivo activity of cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A in psoriasis patients using a cocktail approach. METHODS: Patients with moderate to severe chronic plaque psoriasis (n = 21) received single oral doses of sensitive probe substrates for CYP1A2 (caffeine 100 mg), CYP2C9 (warfarin 10 mg), CYP2C19 (omeprazole 20 mg), CYP2D6 (metoprolol 50 mg), and CYP3A (midazolam 2 mg) on day 1, followed by 12 weeks of subcutaneous risankizumab treatment of 150 mg once every 4 weeks from day 8 to day 92, and again the same cocktail of substrates on day 98. Serial blood samples were collected for determination of the CYP probe drugs and metabolites with and without risankizumab. Trough samples were collected for risankizumab. RESULTS: The 90% confidence intervals (CIs) for the area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC∞) ratios for the CYP probe substrates administered with risankizumab versus without risankizumab were within the default 0.8-1.25 equivalence bounds. Similar results were observed for maximum plasma concentration (Cmax), except for omeprazole, for which the lower bound of the 90% CI for Cmax (0.73) extended slightly below the default equivalence limit. No differences were observed in metabolite-to-parent drug Cmax or AUC ratios with risankizumab versus without risankizumab. Risankizumab trough plasma concentrations significantly exceeded those of the phase III regimen of risankizumab in psoriasis (150 mg subcutaneously at weeks 0 and 4 and every 12 weeks thereafter). CONCLUSIONS: Risankizumab did not affect the in vivo activity of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A enzymes in patients with moderate or severe plaque psoriasis and therefore has no potential for drug interactions through these enzymes. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02772601.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Khatri A, Cheng L, Camez A, et al. Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis. Clin Pharmacokinet. 2019. PMID: 30574672. doi:10.1007/s40262-018-0730-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。